TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients

Study Number

3760823

Phase

Age Group

Adult

Principal Investigator

Purpose

The purpose of this single- arm, open-lable, dose escalation + dose expansion study is to evalulate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had failure with or are intolerant to TKI treatments.

Check your eligibility for this trial

Check now

Full Title

A single-arm, open-label, Dose Escalation + Cohort Expansion Phase 1 Trial to Determine the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-678 given orally to Patients with Refractory or Relapsed Chronic Myelogenous Leukemia

ClinicalTrials.Gov ID

NCT05434312

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.